|Pack Size||Qty||Price Per Pill or Unit||Price||Offer|
|30 Tablet/s||US$ 0.24||US$ 7.24||
|60 Tablet/s||US$ 0.24||US$ 14.46||
|90 Tablet/s||US$ 0.24||US$ 21.70||
|US Brand Name||Glycomet GP|
|Generic Name||Metformin + Glimepiride|
Glycomet GP (500+1) mg is a prescription treatment for type 2 diabetes when diet, exercise, and a single antidiabetic agent (Glimepiride or metformin alone) do not result in adequate glycaemic control. The antidiabetic agent lowers blood glucose by stimulating the release of insulin from pancreatic beta cells.
Glyocomet GP is administered once daily during breakfast or the first main meal. Due to prolonged release formulation, Glycomet GP must be swallowed whole with water and not crushed or chewed. The combination medicine should not be given to paediatric patients as the safety and effectiveness of this antidiabetic agent have not been established.
Contraindications for Glimepiride:
— Hypersensitivity to Glimepiride, other sulphonamides, other sulfonylureas, or any of the ingredients of Glycomet GP
— In pregnant and breastfeeding women
No experience has been gained concerning using Glimepiride in patients with severe liver function difficulties and dialysis patients. A change over to insulin is indicated to achieve optimal metabolic control in such patients.
Contraindication for Metformin:
— Hypersensitivity to metformin or any of the excipients
— Severe Kidney failure
— Any acute metabolic acidosis
— Conditions with the potential to alter renal function, such as:
✓ Severe infection
✓ Intravascular administration of iodinated contrast agents
— The acute, chronic disease may cause tissue hypoxia such as:
✓ Recent myocardial infarction
✓ Cardiac or respiratory failure
— Hepatic impairment
— Acute alcohol intoxication, alcoholism
The administration of oral hypoglycaemic drugs such as tolbutamide has been reported to be associated with increased cardiovascular mortality compared to treatment with diet alone or in combination with insulin.
Lactic acidosis (when a lactic acid product exceeds the lactic acid clearance) is a rare but serious metabolic complication that can occur due to metformin accumulation during treatment with Glycomet GP; when it occurs, it is fatal in about 50% of cases. Lactic acidosis is a medical emergency that must be treated in a hospital setting.
Hypoglycemia (deficiency of glucose in the bloodstream)- All sulfonylurea drugs, including Glycomet GP, can produce severe hypoglycemia. Appropriate dosage and instructions are important to avoid hypoglycaemic episodes.
Loss of control of blood glucose- When a patient receives an antidiabetic regimen and is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycaemic control may occur. It is important to pause the diabetic regime and temporarily administer insulin at such times. The oral antidiabetic may be reintroduced after the acute episode is resolved.
Alcohol intake-Patients should be warned against excessive alcohol intake while receiving metformin formulation.
The common side effects associated with the use of Glycomet GP (500+1) mg are nausea, diarrhoea, constipation, vomiting, and metallic tastes may occur. These adverse effects are generally dose-related and resolve when the dose is reduced. Other side effects include headache, dizziness, urticaria, rash, erythema, flushing, thrombocytopenia, leukopenia, hemolytic anaemia, etc.